Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ:AVXL)

4.545 -0.155 (-3.30%)
Streaming Delayed Price Updated: 10:13 AM EST, Feb 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Anavex Life Sciences Corp. – AVXL
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
From Pomerantz LLP
Via GlobeNewswire
AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee ↗
Via Stocktwits
Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update ↗
Via Stocktwits
News headline image
What to Expect from Anavex Life Sciences's Earnings ↗
 
Via Benzinga
News headline image
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Anavex Stock Slides After Hours On EMA Panel’s Negative Alzheimer’s Drug Opinion — Retail Traders Talk Buyout Potential ↗
Anavex said on Friday that the CHMP has indeed adopted a negative opinion “as expected.” 
Via Stocktwits
News headline image
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Anavex (AVXL) Q4 2025 Earnings Call Transcript ↗
Anavex (AVXL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug ↗
Anavex ended the quarter with cash and cash equivalents of $102.6 million. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Anavex Life Sciences Corp (NASDAQ:AVXL) Surges on Better-Than-Expected Q4 2025 Earnings ↗
Anavex Life Sciences stock surges after reporting a smaller-than-expected Q4 2025 loss, beating EPS estimates and boosting investor confidence. 
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
From Pomerantz LLP
Via GlobeNewswire
News headline image
Anavex Retail Traders See Silver Lining In EMA Committee Postpones Alzheimer’s Drug Verdict: Delay 'Actually A Positive Sign' ↗
The CHMP issued a negative trend vote but postponed its final decision to December. 
Via Stocktwits
News headline image
Top movers analysis one hour before the close of the markets on 2025-11-14: top gainers and losers in today's session. ↗
Here are the top movers in Friday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
Discover the top movers in Friday's pre-market session. ↗
Discover the top movers in Friday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
AVXL Shares Slump Pre-market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug ↗
The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list. 
Via Stocktwits
News headline image
Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug? ↗
The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window. 
Via Stocktwits
News headline image
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group ↗
Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's progression and long-term efficacy over 144 weeks. 
Via Benzinga
News headline image
Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up ↗
The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization. 
Via Stocktwits
Anavex Life Sciences Stock Rises After Experimental Alzheimer’s Drug Slows Cognitive Decline In Study ↗
After 48 weeks, patients receiving 30 mg once-daily oral Blarcamesine demonstrated barely detectable cognitive decline, the company said. 
Via Stocktwits
News headline image
Anavex Life Pre-Treatment Prevented Cognitive Impairment In Animal Model of Alzheimer's Disease, New Publication Shows ↗
Anavex published data showing blarcamesine prevented amyloid-related brain damage in mice, supporting SIGMAR1 as a target for Alzheimer's prevention. 
Via Benzinga
News headline image
Anavex Life Sciences: Early Blarcamesine Treatment Cuts Alzheimer's Progression by 20 Months ↗
Anavex reported that early use of blarcamesine in Alzheimer's trials led to sustained cognitive and functional improvements over 4 years. 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.